Know Cancer

forgot password

An Open-label Phase IIa, Non-randomised, Study of Alpharadin® in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Endocrine Therapy

Phase 1/Phase 2
Open (Enrolling)
Breast Cancer, Bone Metastases

Thank you

Trial Information

An Open-label Phase IIa, Non-randomised, Study of Alpharadin® in Breast Cancer Patients With Bone Dominant Disease no Longer Considered Suitable for Endocrine Therapy

Inclusion Criteria:

1. Female, and either post-menopausal (cessation of menses for more than 1 year) or
surgically sterile (has had a documented bilateral oophorectomy and/or documented
hysterectomy) or in therapy-induced premature menopause with LHRH agonists. If of
childbearing potential the result of a urine human chorionic gonadotropin pregnancy
test, performed on the same day as and with the result known before study drug
administration, must be negative.

2. Histological or cytological evidence of primary breast cancer.

3. Bone dominant disease (with or without metastases in soft tissue, lymph nodes and/or
skin) with at least one non-irradiated bone metastasis on planar bone
scintigraphy/SPECT ± CT within previous the 12 weeks.

4. Patient has unequivocally progressed on endocrine therapy and further benefit from
endocrine therapy is considered unlikely (progression must be documented based on
imaging and/or other clinically relevant information).

5. Patient has been on bisphosphonate therapy for at least 3 months prior to treatment
start and no change to bisphosphonate therapy is expected during the treatment phase
of the study, or patient is not being treated with bisphosphonates, and such
treatment is not planned to start during the treatment period.

6. Latest endocrine therapy stopped at least 2 weeks prior to treatment start.

7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 - 2.

8. Life expectancy ≥6 months.

9. Patient fulfils the following laboratory requirements:

- White Blood Cell Count (WBC) ≥3,000/mm3

- Absolute Neutrophil Count (ANC) ≥1,500/mm3

- Platelet (PLT) count ≥100,000/mm3

- Haemoglobin (HGB) ≥9 g/dl

- Bilirubin ≤2.0 mg/dl

- Aspartate aminotransferase (AST) and Alkaline aminotransferase (ALT) ≤3 times
upper institutional limit of the normal range

- Serum creatinine ≤2.0 mg/dl

10. Patient must be able and willing to sign an informed consent form indicating that she
is aware of the investigational nature of this study in keeping with the policies of
the institution, and must have provided written authorisation for use and disclosure
of protected health information.

11. Patient must be willing and able to comply with the protocol and agree to return to
the hospital for follow-up visits and examination.

Exclusion Criteria:

1. Received an investigational drug within 4 weeks prior to the administration of
Alpharadin, or is scheduled to receive one during the treatment period.

2. Received chemotherapy, immunotherapy, or external beam radiation therapy within the
last 4 weeks prior to administration of study drug, or has not recovered from acute
ARs as a result of such therapy.

3. Is likely to require chemotherapy or immunotherapy within the 16 weeks treatment

4. Presence of imminent or established spinal cord compression based on clinical
findings and/or MRI.

5. Presence of other currently active (relapse within the last 3 years) malignancy
(except non melanoma skin cancer) that are not breast cancer metastases.

6. Presence of unequivocal visceral metastases requiring chemotherapy treatment in the
next 6 months, based on Investigator's judgement. Brain metastases are allowed only
if well controlled and if not associated with symptoms. Treatment for brain
metastasis should have been completed at least 8 weeks prior to treatment start.

7. Patients with any other serious illness or medical condition, such as:

- any uncontrolled infection

- clinical heart failure severe enough to cause marked limitation of activity, and
who is only comfortable at rest; or heart failure more severe than this (NYHA
Heart Failure Class III or IV)

- Crohn's disease or ulcerative colitis

- Bone marrow myelodysplasia

- Unmanageable faecal incontinence

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Changes in bone markers (urine levels of NTX (uNTX) and bone-alkaline phosphatase (ALP)

Outcome Time Frame:

16 weeks

Safety Issue:


Principal Investigator

Robert E Coleman, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Weston Park Hospital, Cancer Research Centre, Academic Unit of Clinical Oncology


Belgium: Federal Agency for Medicinal Products and Health Products

Study ID:




Start Date:

January 2010

Completion Date:

March 2012

Related Keywords:

  • Breast Cancer
  • Bone Metastases
  • Bone markers
  • Safety
  • Breast Neoplasms
  • Neoplasm Metastasis
  • Bone Neoplasms
  • Bone Marrow Diseases